v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Acquisitions (Details)
$ / shares in Units, shares in Thousands, $ in Millions
 1 Months Ended 12 Months Ended
Nov. 13, 2025
USD ($)
payment
$ / shares
Dec. 14, 2023
USD ($)
medicine
$ / shares
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Business Combination [Line Items]              
Contingent value right       $ 1,800 $ 517    
Business acquisition, cash payment, net of cash acquired       6,927 0 $ 43,430  
Goodwill [1]     $ 67,783 71,264 68,527 67,783  
Uncertain tax positions     $ 4,802 [2] $ 4,746 [2] $ 4,530 [2] 4,802 [2] $ 4,494
Metsera [Member]              
Business Combination [Line Items]              
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 65.60            
Number of milestone payments | payment 3            
Business acquisition, cash payment, gross $ 8,000            
Business acquisition, cash payment, net of cash acquired 7,800            
Contingent value right 632            
Stock awards related to pre-acquisition services 475            
Post closing compensation expense 129            
Identifiable intangible assets, net 8,000            
Goodwill 2,200            
Net deferred tax liabilities 1,700            
Contingent consideration liabilities $ 635            
Metsera [Member] | Total Payments to Former Metsera Shareholders [Member]              
Business Combination [Line Items]              
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 20.65            
Contingent value right $ 2,300            
Metsera [Member] | Phase 3 Clinical Trial [Member]              
Business Combination [Line Items]              
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 4.60            
Metsera [Member] | FDA Approval of MET-097i [Member]              
Business Combination [Line Items]              
Business acquisition, per share in cash (in dollars per share) | $ / shares 6.40            
Metsera [Member] | FDA Approval of MET-097i + MET-233i [Member]              
Business Combination [Line Items]              
Business acquisition, per share in cash (in dollars per share) | $ / shares $ 9.65            
Seagen [Member]              
Business Combination [Line Items]              
Business acquisition, per share in cash (in dollars per share) | $ / shares   $ 229          
Business acquisition, cash payment, gross   $ 44,200          
Business acquisition, cash payment, net of cash acquired   43,400          
Post closing compensation expense   476          
Goodwill   17,148          
Net deferred tax liabilities   $ 4,800          
Number of approved medicines | medicine   4          
Gross contractual amount receivable   $ 597          
Uncertain tax positions   48          
Net deferred tax liabilities, gross   (6,300)          
Deferred tax assets   $ 1,500          
Pro Forma net loss attributable to Pfizer Inc. common shareholders           1,481  
Shares issued in acquisition (in shares) | shares     0        
Seagen [Member] | Amortization Expense [Member]              
Business Combination [Line Items]              
Pro Forma net loss attributable to Pfizer Inc. common shareholders           553  
Seagen [Member] | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment [Member]              
Business Combination [Line Items]              
Pro Forma net loss attributable to Pfizer Inc. common shareholders           755  
Seagen [Member] | Interest Expense [Member]              
Business Combination [Line Items]              
Pro Forma net loss attributable to Pfizer Inc. common shareholders           984  
Seagen [Member] | Interest Income [Member]              
Business Combination [Line Items]              
Pro Forma net loss attributable to Pfizer Inc. common shareholders           $ 1,200  
[1] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2025 (see Note 17A), our goodwill was reallocated among impacted reporting units. We completed the re-allocation during the first quarter of 2025 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.
[2] In 2025, included in Income taxes payable ($5 million), Other current assets ($5 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.6 billion), Noncurrent deferred tax liabilities ($58 million) and Other taxes payable ($3.0 billion). In 2024, included in Income taxes payable ($103 million), Other current assets ($0.4 million), Noncurrent deferred tax assets and other noncurrent tax assets ($1.5 billion), Noncurrent deferred tax liabilities ($3 million) and Other taxes payable ($2.9 billion).